GOSS Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $9.24M; Operating expenses $35.31M; Income tax (m); Net income $16.90M.
- 2026-03-31: Revenue $16.95M; Operating expenses $61.82M; Income tax (m); Net income -$46.66M.
- 2025-12-31: Revenue $13.80M*; Operating expenses $59.84M*; Income tax -$88.00K*; Net income (m).
- 2025-09-30: Revenue $13.29M; Operating expenses $62.41M; Income tax $0.00; Net income -$48.22M.
Counterparty Name
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Segment
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Operating expenses | Income tax | Net income |
|---|---|---|---|---|
| 2026-06-30 | $9.24M | $35.31M | (m) | $16.90M |
| 2026-03-31 | $16.95M | $61.82M | (m) | -$46.66M |
| 2025-12-31 | $13.80M* | $59.84M* | -$88.00K* | (m) |
| 2025-09-30 | $13.29M | $62.41M | $0.00 | -$48.22M |
| 2025-06-30 | $11.49M | $50.25M | $0.00 | -$38.27M |
| 2025-03-31 | $9.89M | $46.70M | (m) | -$36.64M |
| 2024-09-30 | $9.48M | $43.40M | -$1.13M | -$30.80M |
| 2024-06-30 | $95.84M | $43.76M | $4.43M | $49.23M |
| 2024-03-31 | $0.00 | $41.96M | (m) | -$41.93M |
| 2023-09-30 | $0.00 | $40.49M | $0.00 | -$40.01M |
| 2023-06-30 | $0.00 | $46.30M | $0.00 | -$42.50M |
| 2023-03-31 | (m) | $47.94M | (m) | -$49.16M |
| 2022-09-30 | (m) | $56.02M | (m) | -$59.36M |
| 2022-06-30 | (m) | $53.87M | (m) | -$56.47M |
| 2022-03-31 | (m) | $54.34M | (m) | -$57.78M |
| 2021-09-30 | (m) | $55.66M | (m) | -$60.25M |
| 2021-06-30 | (m) | $55.60M | (m) | -$59.83M |
| 2021-03-31 | (m) | $53.20M | (m) | -$57.64M |
| 2020-09-30 | (m) | $53.57M | (m) | -$57.81M |
| 2020-06-30 | (m) | $65.34M | (m) | -$66.87M |
| 2020-03-31 | (m) | $54.97M | (m) | -$54.07M |
| 2019-12-31 | (m) | (m) | (m) | -$54.70M |
| 2019-09-30 | (m) | $49.99M | (m) | -$48.50M |
| 2019-06-30 | (m) | $46.35M | (m) | -$44.50M |
| 2019-03-31 | (m) | $34.02M | (m) | -$32.61M |
| 2018-12-31 | (m) | (m) | (m) | -$38.79M |
| 2018-09-30 | (m) | $50.02M | (m) | -$49.41M |
| 2018-06-30 | (m) | $33.04M | (m) | -$32.73M |
| 2018-03-31 | (m) | $26.13M | (m) | -$26.04M |
Revenue and expense 6 month
| Period end | Revenue | Operating expenses | Income tax | Net income |
|---|---|---|---|---|
| 2026-06-30 | $26.19M | $97.13M | (m) | -$29.76M |
| 2025-06-30 | $21.38M | $96.95M | $0.00 | -$74.91M |
| 2024-06-30 | $95.84M | $85.71M | $4.43M | $7.30M |
| 2023-06-30 | $0.00 | $94.24M | $0.00 | -$91.66M |
| 2022-06-30 | (m) | $108.22M | (m) | -$114.25M |
| 2021-06-30 | (m) | $108.80M | (m) | -$117.47M |
| 2020-06-30 | (m) | $120.31M | (m) | -$120.94M |
| 2019-06-30 | (m) | $80.37M | (m) | -$77.11M |
| 2018-06-30 | (m) | $59.16M | (m) | -$58.77M |
Revenue and expense 9 month
| Period end | Revenue | Operating expenses | Income tax | Net income |
|---|---|---|---|---|
| 2025-09-30 | $34.67M | $159.36M | $0.00 | -$123.13M |
| 2024-09-30 | $105.32M | $129.11M | $3.30M | -$23.50M |
| 2023-09-30 | $0.00 | $134.73M | $0.00 | -$131.67M |
| 2022-09-30 | (m) | $164.24M | (m) | -$173.61M |
| 2021-09-30 | (m) | $164.46M | (m) | -$177.72M |
| 2020-09-30 | (m) | $173.88M | (m) | -$178.76M |
| 2019-09-30 | (m) | $130.35M | (m) | -$125.61M |
| 2018-09-30 | (m) | $109.19M | (m) | -$108.17M |
Revenue and expense 12 month
| Period end | Revenue | Operating expenses | Income tax | Net income |
|---|---|---|---|---|
| 2025-12-31 | $48.47M | $219.20M | -$88.00K | -$170.37M |
| 2024-12-31 | $114.70M | $174.62M | $893.00K | -$56.53M |
| 2023-12-31 | $0.00 | $183.76M | $0.00 | -$179.82M |
| 2022-12-31 | $0.00 | $218.59M | $0.00 | -$229.38M |
| 2021-12-31 | (m) | $216.12M | (m) | -$234.00M |
| 2020-12-31 | (m) | $233.96M | (m) | -$243.36M |
| 2019-12-31 | (m) | $186.14M | $0.00 | -$180.31M |
| 2018-12-31 | (m) | $148.99M | $0.00 | -$146.97M |
| 2017-12-31 | (m) | $6.65M | $0.00 | -$6.77M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |